Navigation Links
Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Date:9/24/2008

, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Contacts:

Dr Jurgen Raths, President and CEO,

Tel.: +41-61-417-96-60;

Harry Welten, MBA, CFO and Senior Vice President,

Tel.: +41-61-417-96-65;

Paul Verbraeken, Head of Corporate Communications,

Tel.: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014  Rock Creek ... biotechnology company, today announced that the Food and Drug ... will provide comments on RCP,s Investigational New Drug ("IND") ... clinical trial in the US. Dr. ... agency,s review and comments on our IND. When we ...
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... SCHAUMBURG, Ill. , Jan. 19 ... pharmaceutical company, today announced that it has launched ... per 10 mL and 90 mg per 10 mL.  Pamidronate disodium ... Aredia®, is a bone resorption inhibitor.  The 2008 ...
... , FRANKLIN LAKES, N.J. , Jan. ... MHS ) are scheduled to present at the following investor conferences: , ... the Jeffries 2010 Global Healthcare Services Conference on Monday, January 25, ... hotel in New York ; , David B. Snow Jr. ...
Cached Medicine Technology:Sagent Pharmaceuticals Launches Pamidronate Disodium Injection 2Medco to Present at Upcoming Investor Conferences 2
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit ... his clients. He’s also known for his support of local non-profits ... to combine the two and is excited to announce that his ... and Girls Club. , The funds are the result of Francis’ ... Francis sent out emails and asked his clients to put out ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... 2014 Utah Valley Entrepreneurial Forum Top ... awards being bestowed to companies in revenue, and pre-revenue ... community with recognition for new ideas as well as ... revenue. , 25 Under 5 highlights outstanding Utah entrepreneurs ... under 5 years old. Award recipients were recognized at ...
(Date:7/12/2014)... 2014 Restore My Vision Today is ... Pearson, a couple boasting very impressive credentials on the ... Vision Today as a way to help consumers do ... in their respective patients’ treatments . , ... “secret” trove of pertinent information relevant to eye care ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... Susan G. Komen for the Cure(R) Advocacy Alliance applauds ... Kay Bailey Hutchison (R-TX) to reignite the war on ... Cancer ALERT ( A ccess to L ife-saving ... T reatment) Act. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO )"It,s ...
... Hospital in Houston has agreed to pay the ... it defrauded the federal Medicare program, the Justice ... improperly increased charges to Medicare patients in order ... addition to its standard payment system, Medicare pays ...
... of government strategy to tackle issue , , THURSDAY, ... rivers were found to be tainted with traces of ... from the U.S. Environmental Protection Agency and Baylor University. ... two types of antidepressants were among the seven types ...
... KINGSTON, R.I. March 26, 2009 Two University of ... is regulated by reactive oxygen species (ROS) -- a type ... this protein normally behaves in human cells and may help ... student David J. Kemble and Professor Gongqin Sun in the ...
... 25% annually, according to Millennium Research GroupWALTHAM, Mass., ... (MRG,s) US Markets for Large-Joint Reconstructive Implants ... fastest-growing segment of the large-joint reconstructive implant market ... rate of over 25%. Hip resurfacing is ...
... March 26 /PRNewswire-USNewswire/ -- The U.S. ... today that 10,000 women have received surgery for ... a devastating vaginal injury affecting millions of women ... most of those with the condition lack access ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Senators Kennedy, Hutchison for Bipartisan Cancer Alert Act 2Health News:Houston's Methodist Hospital to Pay U.S. More Than $9 Million to Resolve Allegations of Overcharging Medicare 2Health News:Fish in U.S. Rivers Tainted With Common Medications 2Health News:URI scientists reveal mechanism that regulates cancer-causing gene 2Health News:Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement 2Health News:Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement 3Health News:Major Milestone Reached in Global Maternal Health 2
...
... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
Stylish yet conservative, these classics are reliable, comfortable and durable....
Inquire...
Medicine Products: